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ABSTRACT
Objective N-methyl-D-aspartate receptor antibody
(NMDAR-Ab) encephalitis is a well-recognised clinico-
immunological syndrome that presents with
neuropsychiatric symptoms cognitive decline, movement
disorder and seizures. This study reports the clinical
features, management and neurological outcomes of
paediatric NMDAR-Ab-mediated neurological disease in
the UK.
Design A prospective surveillance study. Children with
NMDAR-Ab-mediated neurological diseases were
voluntarily reported to the British Neurological
Surveillance Unit (BPNSU) from November 2010 to
December 2011. Initial and follow-up questionnaires
were sent out to physicians.
Results Thirty-one children fulﬁlled the criteria for the
study. Eight presented during the study period giving an
incidence of 0.85 per million children per year (95% CI
0.64 to 1.06); 23 cases were historical. Behavioural
change and neuropsychiatric features were present in
90% of patients, and seizures and movement disorders
both in 67%. Typical NMDAR-Ab encephalitis was
reported in 24 children and partial phenotype without
encephalopathy in seven, including predominantly
psychiatric (four) and movement disorder (three). All
patients received steroids, 22 (71%) received intravenous
immunoglobulin, 9 (29%) received plasma exchange,and
10 (32%) received second-line immunotherapy. Of the
23 patients who were diagnosed early, 18 (78%) made
a full recovery compared with only 1 of 8 (13%) of the
late diagnosed patients (p=0.002, Fisher’s exact test).
Seven patients relapsed, with four needing additional
second-line immunotherapy.
Conclusions Paediatric NMDAR-Ab-mediated
neurological disease appears to be similar to adult
NMDAR-Ab encephalitis, but some presented with a
partial phenotype. Early treatment was associated with a
quick and often full recovery.
INTRODUCTION
N-methyl-D-aspartate receptor antibody (NMDAR-
Ab) encephalitis is the most widely studied of the
recently described autoimmune encephalitidies.1 2
Primarily affecting young adults and children, the
typical presentation is with subacute onset behav-
ioural change, neuropsychiatric features and sei-
zures, usually progressing to movement disorder,
hypoventilation, reduced consciousness and auto-
nomic instability.3 The association with an under-
lying ovarian teratoma4 depends on age and sex,
and is most frequent (up to 50%) in young
women.5 6 The paediatric presentation has been
described as more ‘neurological’ than the more psy-
chiatric presentation in adults.6 7
Patients are treated with tumour resection if
required, ﬁrst-line immunotherapy (intravenous
and/or oral steroids, intravenous immunoglobulin,
and/or plasma exchange (PLEX)) and second-line
immunotherapy (cyclophosphamide or rituximab) if
indicated.4 More than 75% of all patients have a
substantial recovery, with early recognition and
treatment predictive of a good outcome.4 This infor-
mation, however, has been largely gathered from
patient cohorts, mainly comprising retrospective
data,6 7 and as yet, no incidence rates and outcomes
have been reported from population-based pro-
spective cohorts. Here, we report a prospective sur-
veillance study in the UK to ascertain incidence,
clinical, investigative features and outcomes of child-
hood (age <18 years) NMDAR-Ab encephalitis.
METHOD
Study design
A UK-wide prospective surveillance study of
NMDAR-Ab encephalitis in children (1–17 years 11
months), in conjunction with the British Paediatric
Neurology Surveillance Unit (BPNSU), recruited
patients from November 2010 to December
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What is already known on this topic?
▸ Autoimmune encephalitis is increasingly
recognised as an important cause of
encephalitis in adults and children.
▸ Paediatric N-methyl-D-aspartate
receptor-antibody (NMDAR-Ab) encephalitis is
a complex multisymptom disease, but treatable
with immunotherapy.
What this study adds?
▸ Paediatric NMDAR-Ab encephalitis can present
with a single clinical feature predominating.
▸ Plasma exchange in the early stages of disease
may be associated with a quicker recovery to a
premorbid level of functioning.
▸ Most patients, particularly those diagnosed and
treated early, make a full recovery, and this
should be the aim of therapy.
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2011 (13 months). Through a web-based portal (http://www.
bpnsu.co.uk/), monthly notiﬁcation emails were sent to all regis-
tered consultant paediatric neurologists during the study period.
Clinicians replied to the email notifying any cases or conﬁrming
‘nothing to report’. Upon receipt of a positive notiﬁcation, the sur-
veillance unit provided the investigating team with a BPNSU case
number and clinician contact details.
Case deﬁnition and identiﬁcation
The case deﬁnition for this study was ‘any child or young adult,
who presents with new onset of acute behavioural change, sei-
zures, dystonias or dyskinesias and with antibodies to the NR1
subunit of the NMDAR in the serum and/or CSF’. Clinicians
were asked to report both new and previous cases. The study
team contacted the clinician directly and sent two question-
naires: one at notiﬁcation and one at 12 months (see online sup-
plementary information). ‘Late diagnosis’ was deﬁned as
identiﬁcation of NMDAR-Abs >6 months from disease presen-
tation; 19 of these cases have been reported previously as part
of a case series, cohort or as case reports.8–10 Treatment
response was derived from the clinician responses in the ques-
tionnaire, and mRS (modiﬁed Rankin Scale) for children
(appended to the follow-up questionnaire) was used to measure
outcomes.
Statistical analysis
Descriptive statistics were used to summarise the key compo-
nents of the dataset. Fisher’s exact test (two-tailed) was used to
compare clinical details in GraphPad Prism V.6.
Approvals
The study proposal was approved by the BPNSU executive com-
mittees. The study had approval from the UK Multicentre
Research Ethics Committee and the Oxfordshire Regional
Ethical Committee A (07/Q1604/28) with a substantial amend-
ment (1) approved on 30 April 2010.
RESULTS
Over the study period (13 months), 1526 email responses were
received from 171 clinicians reporting 35 known and 10 new
cases. A review of the Oxford neuroimmunology database con-
ﬁrmed the positive NMDAR-Ab results. Three children with
positive results were identiﬁed from the Oxford database and
not reported to the BPNSU. Of the 35 completed questionnaires
received, 31 cases from 13 different centres met the case study
deﬁnition. Seven of these patients had been diagnosed late (over
6 months). Four patients were excluded; one was too old at the
time of presentation (19 years old); the second patient was
excluded as his NMDAR-Ab positivity was low and his serum
immunoglobulin (Ig)G also bound to other antigens suggesting
non-speciﬁcity, possibly due to previous intravenous immuno-
globulin (IVIG) treatment causing raised serum IgG levels; two
further cases were excluded as they did not fulﬁl the clinical cri-
teria of the case deﬁnition. Both these patients presented with
white-matter disease now known to be associated with
NMDAR-Abs.11 These cases and cases from other centres have
been reported separately.12 The remaining 24 cases were diag-
nosed within 8 weeks of symptoms onset, but only eight within
the study period.
Demographics
Patients’ demographics are described in ﬁgure 1. The majority
of patients were female (23/31; 74%) with a median age of
8 years (range 22 months–17 years). Male patients, despite the
small numbers, were older (median 11 years; range 6–17 years;
p=0.03); 55% of the patients were Caucasian (ﬁgure 1). There
were eight patients newly diagnosed over 13 months giving an
estimate of incidence, based on a paediatric population of 12
million in the UK (http://www.ons.gov.uk), of 0.85 per million
children per year (95% CI 0.64 to 1.06).
Clinical features of all patients
Good premorbid health and development were seen in 28/31
(90%); two patients had an uncomplicated Tetralogy of Fallot
repair in infancy and another patient had a XXX karyotype
with developmental delay. There was no signiﬁcant family
history of autoimmune disease.
The clinical features are summarised for each patient in
table 1A, B. Behavioural change and/or neuropsychiatric fea-
tures were the initial presenting symptom in 90% (28/31).
During the course of the disease, seizures and new onset
movement disorders were both seen in 21/31 patients (68% in
each case). Sleep dysfunction was reported in 16/31 (52%)
and autonomic features were found in 12 (39%) cases, with
cardiac abnormalities including one cardiac arrest, and hypo-
ventilation requiring intensive care support in three cases.
Individual patients exhibited myoclonus, neuromyotonia or
transient limb weakness. Partial phenotypes, predominant
movement (n=3) or psychiatric features (n=4), were reported
more frequently in boys (n=4) (4/8 boys vs 3/23 girls,
p=0.05, Fisher’s exact test). The patients with partial
Figure 1 Demographic data of UK patients with N-methyl-D-
aspartate receptor-antibody encephalitis. Age of onset stratiﬁed to sex
(A) showing an overall female predominance. Boys were more likely to
present at over the age of 5 years (p=0.03, Fisher’s exact test).
Ethnicity of the patients (B), 14 patients (45%) were non-Caucasian.
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phenotypes had at least one additional symptom (behavioural
change, movement disorder, psychiatric features or seizures)
and were not monosymptomatic (table 1).
Paraclinical features of all patients
Cerebrospinal ﬂuid (CSF) was abnormal with pleocytosis in
45% (13/29). Eight of 12 (67%) had intrathecal oligoclonal
bands. Seven serum/CSF pairs were positive for NMDAR-Abs;
two CSFs sent later during the disease course were negative.
MRI scans were normal in 20/31 (65%), but high signal changes
in cortical (frontal, frontoparietal, temporal, hippocampi), and
subcortical areas (basal ganglia) were seen in 7/31 (23%).
Electroencephalography (EEG) was encephalopathic in the
majority (28/30; 93%). The ﬁnding of extreme delta brush was
not reported. The EEG was normal in two of the cases with
partial phenotypes (Cases 19 and 9). Three patients had a
positive antistreptolysin O titre, one of whom was also positive
for IgM Epstein–Barr virus antibodies. Other antibodies
identiﬁed included antinuclear antibody and extractable
nuclear antigen in one patient, antibasal ganglia antibodies and
voltage-gated potassium channel-complex antibodies
(661 pmol/L) in another.
Table 1 Predominant symptoms at presentation, and outcomes at final follow-up
(A)
Case
number Age: sex
Clinical
features
Time to diagnosis/time
to treatment response
Treatment
group Outcome/ΔmRS score*
2† 14: F BC, S, MD, Sp 6 months/2 days A Full recovery no sequelae/(5)
3 F BC, S, MD 9 months/90 days D Cognitive problems/(3)
4 10: F BC, S >1 year/no response A Cognitive problems/(1)
16 6: M BC, S, MD >1 year/7 days A Seizures, on treatment/(4)
20 10: F BC, S, MD >1 year/no response A Significant disability, relapse, leucoencephalopathy on MRI (0)
28 8: M BC, S, MD 7 months/3 days A One encephalopathic relapse treated with steroids/(2)
Partial phenotypes
19 10: F MD, Sp > 1 yr/28 days A Symptom recurrence when unwell (1)
(B)
Case
number Age: sex
Clinical
features
Time to diagnosis/time
to treatment response
Treatment
group Outcome/ΔmRS score†
1 14: F BC, S, MD 1 month/90 days D Full recovery no sequelae/(3)
5 3: F BC, S 1 week/7 days A Full recovery no sequelae/(4)
6 5: F BC, S, MD 1 month/14 days C Antibodies remain high, cognitive problems/(3)
7 9: M BC, S(EPC),MD 2 months/90 days A Full recovery no sequelae/(3)
9 2: F BC, S, MD, Sp 5 weeks/7 days A Full recovery no sequelae/(4)
10 14: F BC, S, MD, 1 week/29 days D One relapse treated with IV/PO steroids and MMF, full eventual recovery no
sequelae/(5)
11 2: F BC, S, MD <1 week/72 days D Full recovery no sequelae/(4)
12 8: F BC, S, MD 2 months/60 days C Full recovery no sequelae/(3)
13 15: F BC, S, MD, Sp A Lost to follow-up
14 13: F BC, S, MD, Sp,
NMT
1 week/14 days A Relapse at 1 year treated with AZT and MMF, full eventual recovery/(2)
15 2: F BC, S, MD 2 weeks/30 days A Ongoing seizures, cognitive problems, antibodies elevated/(3)
17 4: F BC, S, MD 2 weeks/30 days A Developmental arrest same as predisease stage, cognitive and behavioural
problems (3)
22 17: F BC, S, MD 3 weeks/3 days B Full recovery no sequelae/(5)
24 14: F BC, S, MD 1 month/ A Cognitive problems and seizures/(2)
26 3: F BC, S, MD 1 month/28 days D Full recovery no sequelae/(1)
27 11: M BC, MD 12 days/8 days A Full recovery no sequelae/(5)
30 2: F BC, MD 2 weeks/19 days A Cognitive and behavioural problems/(2)
31 2: F BC, MD 4 weeks/67 days D Full recovery no sequelae/(5)
Partial phenotypes
8 17: M NPsych, BC, S 3 weeks/14 days B Full recovery no sequelae/(4)
18 5: F MD, S, Sp <1 week/7 days A Full recovery no sequelae/(3)
21 12: M MD, NPsych 8 weeks/7 days A Full recovery no sequelae/(1)
23 16: M NPsych , BC 1 month/7 days C Two relapses before MMF, none since started (1)
25 15: F NPsych, BC 2 months/2 days D Relapse treated with steroids, cyclophosphamide and rituximab (4)
29 14: M NPsych, BC 2 months/5 days A Relapse treated with PLEX and second-line immunotherapy; eventual full
recovery (0)
(A) lists patients with late diagnosis; (B) lists patients diagnosed within 8 weeks from symptoms onset. Patients with partial phenotypes were defined based on a lack of
encephalopathy as evaluated by clinician.
*Outcome at final follow-up. ΔmRS score from nadir to 12-month postpresentation.
†Denotes patient with ovarian teratoma.
AZT, azathioprine; BC, behavioural change; EPC, epilepsia partialis continua; IV/PO, intravenous/oral; MD, movement disorder; MMF, mycophenolate mofetil; NMT, neuromyotonia;
NPsych, neuropsychiatric; PLEX, plasma exchange; S, seizures; Sp, speech dysfunction.
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Clinical response to initial therapy: speed and extent
All patients received steroids; 22 (71%) received IVIG, 9 (29%)
received PLEX and 10 (32%) received second-line immunother-
apy. Four treatment groups were identiﬁed within the whole
cohort of 31 patients (ﬁgure 2A). The most frequently used
(61%) were IVIG and steroids (Group A); PLEX was added to
these in two patients (Group B). Three patients had IVIG, ster-
oids, no PLEX, but second-line immunotherapy (Group C).
Seven patients had steroids, IVIG, PLEX and second-line
immunotherapy (Group D). A total of 10 (32%) patients were
treated with second-line or long-term immunotherapy using
cyclophosphamide (n=3), rituximab (n=3) or both (n=3), with
mycophenolate mofetil (MMF) initiated in one patient. No sig-
niﬁcant treatment complications/side effects were reported in
any of the 31 patients. Eighteen of 31 (58%) patients showed a
response to immunotherapy within 30 days, but in three
patients, this took up to 90 days. Thirteen patients required
intensive care support during their illness (13/31; 42%). The
median length of patient stay in hospital was 60 days (range
10–365 days), and four (range 1 day–7 days) other health/
medical professionals were needed during admission for each
case (ﬁgure 3). There was no correlation between age of presen-
tation and response to immunotherapy, and no relationship
between initial response to immunotherapy and outcome at
12 months (table 1). However, 89% (8/9) patients who received
PLEX during their initial treatment made a full eventual recov-
ery compared with 47% receiving IVIG and steroids only
(p=0.049, Fisher’s exact test), although this might have been
confounded by additional second-line immunotherapies, as 7/9
of the patients had also received second-line immunotherapy.
Comparison of clinical response between early
and late diagnosis groups
Late diagnosis (>6 months)
Seven patients were not tested for NMDAR-Abs until over
6 months from symptom onset (table 1A). Despite the delay in
diagnosis, all had received steroids and/or IVIG, and one had
MMF (Case 3). One child (Case 2), who responded to ﬁrst-line
immunotherapy, was found to have NMDAR-Abs 6 months
after initial presentation, while asymptomatic and off treatment,
and was consequently found to have an ovarian teratoma. The
teratoma was removed and the patient remained asymptomatic
with no relapses. The remaining six patients still suffer from
ongoing behavioural, cognitive problems and seizures up to
5 years from initial presentation, and one child (Case 20) was
intractable to all treatment. The median mRS score at nadir was
5 (range 2–5), and 2 (range 0–5) at 1-year follow-up. However,
six patients continued to make progress postdischarge, despite
limited or no ongoing treatment (ﬁgure 2B).
Early diagnosis (within 8 weeks)
Twenty children (65%) were diagnosed within 8 weeks of
symptom onset, with a median time of 3 weeks from presenta-
tion to diagnosis (no patients were diagnosed between 8 weeks
and 6 months). The clinical details are summarised in table 1B.
The seven patients with partial phenotypes (Cases 8, 18, 19, 21,
23, 25, 29) were diagnosed 3 weeks later than the patients pre-
senting with full NMDAR-Ab encephalitis phenotypes. At last
follow-up (12–60 months), 78% (18/23) of patients with early
diagnosis had made a full recovery with no sequelae and were
rated an mRS score of 0 compared with the late diagnosed
group where only one patient (Case 2) made a full eventual
recovery (ﬁgure 2C, p=0.0011, Fisher’s exact test). The median
mRS score at nadir was 4 (range 2–5), and 1 (range 0–4) at
1-year follow-up. Eight early diagnosed patients, seven with
typical features of NMDAR-Ab encephalitis and one predomin-
antly neuropsychiatric, made a full recovery within 12 months.
Figure 2 (A) Pie chart showing the four treatment groups of the
whole cohort. Group A had intravenous immunoglobulin and oral/
intravenous steroids only (ﬁrst-line) and no plasma exchange (PLEX);
Group B had ﬁrst-line immunotherapy and plasma exchange; Group C
had ﬁrst-line immunotherapy, no PLEX and second-line immunotherapy;
Group D had all the treatments (ﬁrst-line, PLEX and second-line
immunotherapy). (B) Graph to show the late diagnosed patient group
continues to make progress over time despite no aggressive or
long-term treatment. (C) Table summarises outcomes showing that all
patients diagnosed early make a full/partial recovery (p=0.0011**,
χ2 for trend).
Figure 3 Bar chart to show number and range of allied health
professionals and other medical specialities required in the
management of N-methyl-D-aspartate receptor-antibody neurological
disease in paediatric patients in the UK.
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Five of these eight patients (63%), received PLEX as part of
their initial treatment. Out of the four others who received
PLEX, three also made a full recovery. Five of 23 (22%) patients
had not made a full recovery with ongoing cognitive problems
and learning difﬁculties, and one has refractory seizures requir-
ing treatment with multiple anti-epileptic drugs (AEDs) (Case
15) (table 1A, B). Four out of these ﬁve received only steroids
and IVIG as treatment.
Relapses
Seven patients (23%) had a clinical relapse, which was also con-
ﬁrmed by further antibody testing, (Cases 10, 14, 20, 23, 25,
28, 29); six out of seven relapsing patients (86%) had received
steroids and IVIG only as their initial treatment. The median
time to relapse from original presentation was 12.5 months
(range: 2–60 months). The clinical presentation at the time of
relapse was similar to acute but milder in severity. All relapses
were treated with ﬁrst-line immunotherapy with additional
PLEX in one. Four of the seven (57%) patients went on to
receive second-line or long-term immunotherapy at the time of
relapse, with no further relapse, and full recovery in three
patients. Only one patient had more than one relapse (Case 23).
DISCUSSION
NMDAR-Ab-associated neurological disorders are now well
recognised in children who represent around 40% of the total
number of cases.5 6 As most studies were done retrospectively
on patients with well-deﬁned NMDAR-Ab encephalitis,5 7 the
incidence of this condition and the existence of less typical phe-
notypes has not been clear. In this prospective study, we gath-
ered details on eight NMDAR-Ab-positive children presenting
in the UK between November 2010 and December 2011, and
an additional 23 who had already been identiﬁed as positive for
serum NMDAR-Abs. From our data, we estimate the incidence
to be 0.85/million children/year. The BPNSU relies on voluntary
reporting by clinicians and, hence, could result in underestima-
tion of the true incidence.
Our cohort had demographics similar to previously reported
cohorts with female predominance and only 55%
Caucasians.3 5 6 Only one girl had an ovarian teratoma. By con-
trast with a previously reported paediatric case series suggesting
that children are more likely to present with a neurological
rather than psychiatric phenotype,7 behavioural change and/or
neuropsychiatric symptoms were reported in 90% of children.
Nine patients (31%) presented under the age of 3 years conﬁrm-
ing recent reports, and highlighting the importance of testing
for NMDAR-Ab even in very young children.13
We did not identify a purely monosymptomatic group, but
some patients (partial phenotypes) were not encephalopathic.
These patients had additional associated features (particularly
cognitive) in keeping with symptoms seen with NMDAR hypo-
function. Although these were subtle, their identiﬁcation was
important in managing the patients appropriately and screening
for the associated neoplasms. It remains unclear whether the
treatment prevented these patients from developing full-blown
encephalopathy, but the time from symptom onset to treatment
in patients with partial phenotypes was longer than in patients
presenting with NMDAR-Ab encephalitis. The psychiatric/move-
ment disorder predominant disease was seen more frequently in
male patients, in contrast with the overall female predominance.
These phenotypical differences between the sexes were recently
reported in an adult study14 suggesting that hormonal inﬂuences
on the immune system or on target neurons, may contribute to
the different clinical pictures.
The paraclinical features of our patients were similar to the
previously reported series5 7 with normal MRI brain, encepha-
lopathic EEG with or without epileptiform discharges, and CSF
abnormalities in 45%. The pattern of extreme delta brush was
not reported, although the neurophysiologists would not have
looked for this at the time of the questionnaire completion.15
Positive viral serology was seen in two of the patients; the asso-
ciation between NMDAR-Ab encephalitis and some viruses, par-
ticularly herpes simplex virus (HSV) has previously been
reported by us16 and others,17–19 with either co-occurrence at
onset or HSV encephalitis triggering NMDAR-Ab encephalitis.
All patients received immunotherapy but with different
regimes reﬂecting institutional or clinician preference. Most
patients (78%) diagnosed and treated early made a full recovery
compared with those diagnosed late (>6 months). There
remains no controlled trial to provide high-quality evidence on
the optimal therapeutic strategy for NMDAR-Ab encephalitis,
nor is there the deﬁnitive distinction of what constitutes ﬁrst-
line and second-line therapy. A large cohort analysis6 appears to
suggest the additional beneﬁts of second-line therapy (rituxi-
mab, cyclophosphamide), when ﬁrst-line therapy fails (steroids,
IVIG and PLEX). Certainly, in the current study, the more symp-
tomatic patients and those who relapsed were more likely to
have their treatment escalated in this way. Although we did not
ﬁnd a difference in the long-term outcome between patients
who received second-line immunotherapy or not, full recovery
was seen in nearly all (8/9) patients receiving PLEX; this is
higher than the group which only received steroids and
immunoglobulin (p=0.049), and also higher than the reported
literature.5 6 However, these data are confounded by early treat-
ment and second-line immunotherapy in seven of the nine
(78%) patients, in keeping with a recent report suggesting that
the use of rituximab in paediatric neuroimmune conditions was
associated with greater change in mRS in patients given rituxi-
mab early in their disease course compared with those treated
later.20 A previous study in adults demonstrated a better cogni-
tive outcome in patients treated early.21 Nevertheless, the
response to treatment seen, even in the patients who were diag-
nosed late, support the role of any form of immunotherapy in
all stages of active disease.
The average time of hospital stay in our cohort was 60 days,
higher than in other forms of acquired encephalopathies,22 with
42% requiring admission to intensive care units. Appropriate
management of these patients is challenging and frequently
requires input of a multidisciplinary team. Speech and language
therapists, physiotherapists and occupational therapists form the
mainstay of this fundamental support team and should be
engaged early in disease presentation for maximal beneﬁt to the
patients.
Taken together, careful use of treatment regimes and support-
ive therapies are essential to maximise patient care in this
difﬁcult-to-treat condition. Nevertheless, our study suggests that
complete recovery can be achieved in the majority of paediatric
NMDAR-Ab-mediated neurological diseases. Further studies of
larger prospective cohorts and randomised treatment trials are
still needed to establish the role of second-line immunotherapy
and the duration of treatment needed for this condition.
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